Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Galectin Therapeutics Inc GALT

Healthcare Biotechnology
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GALT)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 26, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 25, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

ACCESS Newswire January 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

GlobeNewswire January 20, 2026

Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud

Newsfile January 19, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

ACCESS Newswire January 18, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

ACCESS Newswire January 17, 2026
View More News ››

Opinion & Analysis (NDAQ:GALT)

Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning

Streetwise Reports December 27, 2018

'The market gets it wrong, again'; analyst raises target price on biotech

Streetwise Reports December 15, 2017

The Calandra Report: More biotech, Bitterroot, CTIX, BCRX, CUR and more

Thom Calandra January 14, 2014
View More Opinion ››

Bullboard Posts (NDAQ:GALT)

GALT Issues

The bull case on GALT is simply stated in this manner: 1.) The FDA has allowed them to go to Phase three on the strength of a portion of...
SPCEO1 - June 25, 2018

Links to articles related to GALT

http://psinvestor.com/galectin-therapeutics-from-an-investor-perspective/ http://emerginggrowth.com/cancers-last-stand-gr-md-02-nearly...
SPCEO1 - June 25, 2018

GALT Trading Signals

Today's rise by 8% was based on the liver therapy provided to patients, which came out with positive numbers.  However, other...
BluSignals - June 14, 2018

RE:RE:Galectin Therapeutics (GALT) Comments on GR-MD-02

IGNORE THIS SPAMMER-DOUGLASTILLO
goldguy007 - July 30, 2014

Galectin Therapeutics (GALT) Comments on GR-MD-02

Galectin Therapeutics (Nasdaq: GALT) announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with...
goldguy007 - July 30, 2014

Was The Sell-Off Justified?

Here is the Seeking Alpha story that helped contribute to the selling. Note that the author is long put options on GALT.http...
goldguy007 - July 30, 2014
View more Bullboard ››

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc. engages in the acquisition, exploration, and development of mineral properties in North ...
View More »

Podcasts